Structural evolution of chars from biomass components pyrolysis in a xenon lamp radiation reactor

The structural evolution of the chars from pyrolysis of biomass components(cellulose, hemicellulose and lignin)in a xenon lamp radiation reactor was investigated. The elemental composition analysis showed that the C content increased at the expense of H and O contents during the chars formation. The values of ΔH/C/ΔO/Cfor the formation of cellulose and hemicellulose chars were close to 2, indicating that dehydration was the dominant reaction. Meanwhile, the value was more than 3 for lignin char formation, suggesting that the occurrence of demethoxylation was prevalent. FTIR and XRD analyses further disclosed that the cellulose pyrolysis needed to break down the stable crystal structure prior to the severe depolymerization. As for hemicellulose and lignin pyrolysis, the weak branches and linkages decomposed firstly, followed by the major decomposition. After the devolatilization at the main pyrolysis stage, the three components encountered a slow carbonization process to form condensed aromatic chars. The SEM results showed that the three components underwent different devolatilization behaviors, which induced various surface morphologies of the chars.

Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody:A case report

BACKGROUND Immune checkpoint inhibitors(ICIs)targeting the programmed death(PD)-1 pathway have substantially changed the clinical management of metastatic urothelial carcinoma(m UC);however,the response rate remains low.There are ongoing efforts to identify robust biomarkers that can effectively predict the treatment response to ICIs.Previous studies have suggested that ERBB2/3 mutations are associated with the efficacy of ICIs in gallbladder carcinoma.CASE SUMMARY We present a 59-year-old man with m UC harboring ERBB2/3 mutations(in-frame insertion of ERBB2 and ERBB3 amplification),negative PD-ligand 1 expression,and low tumor mutation burden.He received anti-PD-1 antibodies and paclitaxel as second-line treatment.After two cycles of treatment,the lung metastases had significantly shrunk,achieving good partial remission.After six cycles of combination therapy,the patient received sindilimab 200 mg once every 3 wk as maintenance monotherapy.At the last follow-up,the patient continued to exhibit a partial response and progression-free survival for as long as 19 mo.CONCLUSION ERBB2/3 mutations may represent a predictive biomarker for selecting a subgroup of m UC patients who will benefit from ICIs.